21 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
3
Vialinin A is a ubiquitin-specific peptidase inhibitor.
Tokyo University of Agriculture
20
Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors.
Harvard Medical School
7
Mechanisms, biology and inhibitors of deubiquitinating enzymes.
Institute For Bio-Medical Research
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
3
Structure-Based Design and Synthesis of Covalent Inhibitors for Deubiquitinase and Acetyltransferase ChlaDUB1 of Chlamydia trachomatis.
Julius-Maximilians-Universitat Wurzburg (JMU)
42
Recent advances in the development of deubiquitinases inhibitors as antitumor agents.
China Pharmaceutical University
7
Identification of covalent fragment inhibitors for Plasmodium falciparum UCHL3 with anti-malarial efficacy.
Purdue University
286
Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.
Zhengzhou University
11
UCH-L3 structure and function: Insights about a promising drug target.
University of Science and Technology
2
Activity-based protein profiling reveals deubiquitinase and aldehyde dehydrogenase targets of a cyanopyrrolidine probe.
Imperial College London
2
Chemical Toolkit for PARK7: Potent, Selective, and High-Throughput.
Leiden University Medical Center
13
Synthesis and evaluation of tiaprofenic acid-derived UCHL5 deubiquitinase inhibitors.
Wayne State University
36
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity.
Rapt Therapeutics
12
Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors.
Dana-Farber Cancer Institute
28
Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.
Progenra
17
Ghrelin O-acyltransferase inhibitors
Glaxosmithkline Intellectual Property Development